Anthropic Says It Will Revolutionize Biology—Some Day

Judgment

Anthropic’s IPO filing shifts the burden to prospective investors: they must decide whether to underwrite a biotech-discovery business—not just an AI tool vendor—even as the filing says drug candidates may never generate revenue and require lab experience it lacks.

Basis

Dario Amodei wrote two years ago he was “open” to AI producing a thousand years of biology progress in five to 10 years; in August he posted on X that AI could cure most human diseases in the next five to 10 years and promised a “deluge of AI-accelerated drugs.” Anthropic promoted Claude’s discovery of a “Crispr-like” enzyme in September. Monday’s IPO filing still touts compressing “decades of scientific progress into years,” but says its teams “need first-hand experience doing scientific research and drug discovery,” must handle hazardous materials, lab equipment and regulations, and tones the enzyme down to “might have the potential... perhaps for gene editing.” The filing warns drug candidates face “lengthy, costly, and uncertain” development and “may never generate revenue.” Mechanism: AI can help sort targets, but discoveries still move through test tube, animals, then people, so trials cannot be hastened simply by adding computers.